Cargando…

Efficacy and toxicity profile of first‐line treatment for extensive‐stage small cell lung cancer: A Bayesian network meta‐analysis

BACKGROUND: The efficacy and toxicity profiles for extensive‐stage small cell lung cancer (ES‐SCLC) are unclear. We aimed to address this gap through a Bayesian network meta‐analysis. METHODS: We performed network analysis from randomized controlled trials comparing these treatments: PD‐(L)1 inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Guo, Yao, Zhuoran, Kang, Kai, Wang, Hui, Luo, Ren, Lu, You
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225202/ https://www.ncbi.nlm.nih.gov/pubmed/36951654 http://dx.doi.org/10.1002/cam4.5750

Ejemplares similares

Efficacy and safety of first-line immunotherapy plus chemotherapy in treating patients with extensive-stage small cell lung cancer: a Bayesian network meta-analysis
por: Zhang, Tianming, et al.
Publicado: (2023)

Efficacy and safety of first-line PD-1/PD-L1 inhibitor combinations for extensive-stage small-cell lung cancer: a Bayesian network meta-analysis
por: Li, Huijuan, et al.
Publicado: (2023)

The Efficacy and Toxicity of Lobaplatin-contained Chemotherapy in Extensive-stage Small-cell Lung Cancer
por: Zhou, Ning-ning, et al.
Publicado: (2018)

Cost-effectiveness of serplulimab as first-line therapy for extensive-stage small cell lung cancer in China
por: Xiang, Guiyuan, et al.
Publicado: (2023)

Economic Evaluation of First-Line Atezolizumab for Extensive-Stage Small-Cell Lung Cancer in the US
por: Wang, Yingcheng, et al.
Publicado: (2021)

Comparison of First-Line Treatments for Patients With Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-analysis
por: Zhou, Ting, et al.
Publicado: (2020)

Real-World Efficacy and Safety of Thoracic Radiotherapy after First-Line Chemo-Immunotherapy in Extensive-Stage Small-Cell Lung Cancer
por: Xie, Zhaoliang, et al.
Publicado: (2023)

Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer
por: Liu, Qiao, et al.
Publicado: (2021)

Immune-checkpoint inhibitors plus chemotherapy versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer
por: Zhou, Fei, et al.
Publicado: (2020)

IMpower, CASPIAN, and more: exploring the optimal first-line immunotherapy for extensive-stage small cell lung cancer
por: Huang, Chengliang, et al.
Publicado: (2020)

Cost-effectiveness analysis of first-line serplulimab combined with chemotherapy for extensive-stage small cell lung cancer
por: Liang, Xueyan, et al.
Publicado: (2023)

First-Line Chemo-Immunotherapy for Extensive-Stage Small-Cell Lung Cancer: A United States-Based Cost-Effectiveness Analysis
por: Liu, Qiao, et al.
Publicado: (2021)

The efficacy and safety of anlotinib combined with platinum-etoposide chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A Chinese multicenter real-world study
por: Zheng, Hao-Ran, et al.
Publicado: (2022)

First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer: clinical developments and future directions
por: Ortega-Franco, A., et al.
Publicado: (2021)

Consideration of Surrogate Endpoints for Overall Survival Associated With First-Line Immunotherapy in Extensive-Stage Small Cell Lung Cancer
por: Zhang, Shuang, et al.
Publicado: (2021)

First-line atezolizumab/durvalumab plus platinum–etoposide combined with radiotherapy in extensive-stage small-cell lung cancer
por: Li, Lijuan, et al.
Publicado: (2023)

Efficacy and Safety of First-Line Immunotherapy in Combination with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis
por: Wang, Bi-Cheng, et al.
Publicado: (2020)

Corrigendum to “Efficacy and Safety of First-Line Immunotherapy in Combination with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis”
por: Wang, Bi-Cheng, et al.
Publicado: (2021)

Systematic review of first-line chemotherapy for chemo-naïve extensive-stage small-cell lung cancer: network meta-analysis
por: Chen, Hao, et al.
Publicado: (2020)

First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis
por: Hotta, Katsuyuki, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Atezolizumab Versus Durvalumab as First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer in the USA
por: Ionova, Yelena, et al.
Publicado: (2022)

Serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis
por: Zhu, Youwen, et al.
Publicado: (2023)

Real-world evaluation of atezolizumab and etoposide-carboplatin as a first-line treatment for extensive-stage small cell lung cancer
por: Kim, Soo Han, et al.
Publicado: (2023)

A phase II study of anlotinib combined with etoposide and platinum‐based regimens in the first‐line treatment of extensive‐stage small cell lung cancer
por: Liu, Chang, et al.
Publicado: (2022)

Real-world outcomes of PD-L1 inhibitors combined with thoracic radiotherapy in the first-line treatment of extensive stage small cell lung cancer
por: Peng, Jianfeng, et al.
Publicado: (2023)

Efficacy of First-Line Immunotherapy Combined With Chemotherapy in Extensive-Stage Small Cell Lung Cancer Patients With Different Brain Metastases Status: A Systematic Review and Meta-Analysis
por: Zhao, Wen Hua, et al.
Publicado: (2023)

Systematic Review and Network Meta-Analysis of Immune Checkpoint Inhibitors in Combination with Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Carcinoma
por: Chen, Hsiao-Ling, et al.
Publicado: (2020)

Chemo-Immunotherapy in First Line Extensive Stage Small Cell Lung Cancer (ES-SCLC): A Systematic Review and Meta-Analysis
por: Sathiyapalan, Arani, et al.
Publicado: (2022)

Clinicopathological Features and First-Line Treatment Outcomes of Geriatric Patients With Extensive-Stage Small Cell Lung Cancer: A Multicenter Study
por: İlhan, Aysegul, et al.
Publicado: (2023)

First-line Immuno-chemotherapy for extensive-stage small-cell lung cancer: A network meta-analysis and cost-effectiveness analysis
por: Zhu, Youwen, et al.
Publicado: (2023)

Clinical comparative investigation of efficacy and toxicity of cisplatin plus gemcitabine or plus Abraxane as first-line chemotherapy for stage III/IV non-small-cell lung cancer
por: Ai, Dan, et al.
Publicado: (2016)

First-Line Treatments for Extensive-Stage Small-Cell Lung Cancer With Immune Checkpoint Inhibitors Plus Chemotherapy: A Network Meta-Analysis and Cost-Effectiveness Analysis
por: Kang, Shuo, et al.
Publicado: (2022)

Potential value of efficacy prediction and treatment of natural killer cells in extensive stage small cell lung cancer
por: Cui, Yanan, et al.
Publicado: (2023)

Efficacy and safety of immune checkpoint inhibitors combined with chemotherapy as first-line treatment for extensive-stage small cell lung cancer: a meta-analysis based on mixed-effect models
por: Zheng, Jianqing, et al.
Publicado: (2023)

First-line pembrolizumab plus chemotherapy for extensive-stage small-cell lung cancer: a United States-based cost-effectiveness analysis
por: Zhu, Youwen, et al.
Publicado: (2021)

Sintilimab maintenance therapy post first-line cytokine-induced killer cells plus chemotherapy for extensive-stage small cell lung cancer
por: Ma, Baozhen, et al.
Publicado: (2022)

Anlotinib plus platinum‐etoposide as a first‐line treatment for extensive‐stage small cell lung cancer: A single‐arm trial
por: Deng, Pengbo, et al.
Publicado: (2022)

A randomized phase 2 trial of apatinib vs observation as maintenance treatment following firstline induction chemotherapy in extensive stage small cell lung cancer
por: Luo, Hao, et al.
Publicado: (2019)

First-line immune-checkpoint inhibitor plus chemotherapy versus chemotherapy alone for extensive-stage small-cell lung cancer: a meta-analysis
por: Landre, Thierry, et al.
Publicado: (2020)

First-Line Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis
por: Zhang, Longfeng, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ebn1u06s3057olvsv30vi1cseu